TABLE 2. Estimated annual number of human papillomavirus (HPV)–attributable cancers,* by cancer type,† HPV type,§ and state — United States,¶ 2012–2016.
| State | Estimated no.** |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| All cancers |
Oropharynx (male and female) |
Cervix |
|||||||
| 9vHPV-targeted | Other HPV | HPV-negative | 9vHPV-targeted | Other HPV | HPV-negative | 9vHPV-targeted | Other HPV | HPV-negative | |
| Alabama |
540 |
40 |
160 |
220 |
10 |
100 |
170 |
20 |
20 |
| Alaska |
60 |
<10 |
20 |
20 |
<10 |
10 |
20 |
<10 |
<10 |
| Arizona |
530 |
40 |
150 |
220 |
10 |
100 |
160 |
20 |
20 |
| Arkansas |
360 |
30 |
100 |
140 |
<10 |
60 |
120 |
10 |
10 |
| California |
3,270 |
260 |
870 |
1,170 |
80 |
510 |
1,120 |
130 |
130 |
| Colorado |
460 |
40 |
130 |
190 |
10 |
80 |
130 |
20 |
20 |
| Connecticut |
370 |
30 |
110 |
150 |
<10 |
70 |
100 |
10 |
10 |
| Delaware |
110 |
<10 |
30 |
40 |
<10 |
20 |
30 |
<10 |
<10 |
| District of Columbia |
60 |
<10 |
10 |
20 |
<10 |
<10 |
20 |
<10 |
<10 |
| Florida |
2,690 |
210 |
780 |
1,170 |
80 |
520 |
730 |
90 |
90 |
| Georgia |
1,050 |
80 |
300 |
400 |
30 |
180 |
320 |
40 |
40 |
| Hawaii |
120 |
<10 |
30 |
50 |
<10 |
20 |
40 |
<10 |
<10 |
| Idaho |
150 |
10 |
40 |
60 |
<10 |
30 |
40 |
<10 |
<10 |
| Illinois |
1,310 |
100 |
380 |
500 |
30 |
220 |
400 |
50 |
50 |
| Indiana |
740 |
60 |
220 |
300 |
20 |
130 |
210 |
30 |
20 |
| Iowa |
330 |
30 |
100 |
120 |
<10 |
50 |
90 |
10 |
10 |
| Kansas |
280 |
20 |
80 |
110 |
<10 |
50 |
80 |
10 |
<10 |
| Kentucky |
590 |
50 |
180 |
230 |
10 |
100 |
170 |
20 |
20 |
| Louisiana |
520 |
40 |
150 |
200 |
10 |
90 |
160 |
20 |
20 |
| Maine |
170 |
10 |
60 |
70 |
<10 |
30 |
30 |
<10 |
<10 |
| Maryland |
550 |
40 |
160 |
220 |
10 |
90 |
160 |
20 |
20 |
| Massachusetts |
660 |
50 |
210 |
290 |
20 |
130 |
150 |
20 |
20 |
| Michigan |
1,000 |
80 |
300 |
410 |
30 |
180 |
260 |
30 |
30 |
| Minnesota |
470 |
40 |
150 |
200 |
10 |
90 |
120 |
10 |
10 |
| Mississippi |
350 |
30 |
100 |
130 |
<10 |
60 |
110 |
10 |
10 |
| Missouri |
710 |
60 |
200 |
290 |
20 |
130 |
200 |
20 |
20 |
| Montana |
100 |
<10 |
30 |
40 |
<10 |
20 |
30 |
<10 |
<10 |
| Nebraska |
170 |
10 |
50 |
60 |
<10 |
30 |
50 |
<10 |
<10 |
| Nevada |
270 |
20 |
70 |
100 |
<10 |
50 |
90 |
10 |
10 |
| New Hampshire |
140 |
10 |
40 |
70 |
<10 |
30 |
30 |
<10 |
<10 |
| New Jersey |
880 |
70 |
250 |
320 |
20 |
140 |
290 |
30 |
30 |
| New Mexico |
170 |
10 |
50 |
60 |
<10 |
30 |
60 |
<10 |
<10 |
| New York |
1,980 |
160 |
530 |
660 |
40 |
290 |
660 |
80 |
80 |
| North Carolina |
1,100 |
90 |
330 |
470 |
30 |
210 |
300 |
40 |
30 |
| North Dakota |
60 |
<10 |
20 |
30 |
<10 |
10 |
10 |
<10 |
<10 |
| Ohio |
1,260 |
100 |
370 |
500 |
30 |
220 |
360 |
40 |
40 |
| Oklahoma |
420 |
30 |
120 |
150 |
<10 |
70 |
130 |
20 |
20 |
| Oregon |
430 |
30 |
120 |
190 |
10 |
80 |
110 |
10 |
10 |
| Pennsylvania |
1,410 |
110 |
420 |
550 |
40 |
240 |
400 |
50 |
50 |
| Rhode Island |
110 |
<10 |
30 |
40 |
<10 |
20 |
30 |
<10 |
<10 |
| South Carolina |
550 |
40 |
170 |
240 |
20 |
100 |
150 |
20 |
20 |
| South Dakota |
80 |
<10 |
20 |
30 |
<10 |
10 |
20 |
<10 |
<10 |
| Tennessee |
780 |
60 |
220 |
310 |
20 |
130 |
230 |
30 |
30 |
| Texas |
2,310 |
200 |
620 |
830 |
50 |
360 |
890 |
110 |
100 |
| Utah |
160 |
10 |
40 |
60 |
<10 |
30 |
50 |
<10 |
<10 |
| Vermont |
60 |
<10 |
20 |
30 |
<10 |
10 |
10 |
<10 |
<10 |
| Virginia |
760 |
60 |
220 |
310 |
20 |
140 |
210 |
30 |
20 |
| Washington |
690 |
50 |
200 |
280 |
20 |
120 |
190 |
20 |
20 |
| West Virginia |
250 |
20 |
70 |
100 |
<10 |
40 |
70 |
<10 |
<10 |
| Wisconsin |
560 |
40 |
170 |
240 |
20 |
100 |
150 |
20 |
20 |
| Wyoming | 40 | <10 | 10 | 20 | <10 | <10 | 10 | <10 | <10 |
Abbreviations: 9vHPV = 9-valent HPV vaccine; ICD-O-3 = International Classification of Diseases for Oncology, Third Edition.
* HPV-attributable cancers are cancers that are probably caused by HPV (https://academic.oup.com/jnci/article/107/6/djv086/872092). Estimates for attributable fraction were based on studies that used population-based data from cancer tissue studies to estimate the percentage of those cancers probably caused by HPV.
† HPV-associated cancers were defined as invasive cancers at anatomic sites with cell types in which HPV DNA frequently is found. All cancers were histologically confirmed. Cervical cancers (ICD-O-3 site codes C53.0–C53.9) are limited to carcinomas (ICD-O-3 histology codes 8010–8671, 8940–8941). Vaginal (ICD-O-3 site code C52.9), vulvar (ICD-O-3 site codes C51.0–C51.9), penile (ICD-O-3 site codes C60.0–60.9), anal (ICD-O-3 site codes C20.9, C21.0–C21.9), and oropharyngeal (ICD-O-3 site codes C01.9, C02.4, C02.8, C05.1, C05.2, C09.0, C09.1, C09.8, C09.9, C10.0, C10.1, C10.2, C10.3, C10.4, C10.8, C10.9, C14.0, C14.2, and C14.8) cancer sites are limited to squamous cell carcinomas (ICD-O-3 histology codes 8050–8084, 8120–8131).
§ “9vHPV-targeted” includes oncogenic HPV types 16, 18, 31, 33, 45, 52, and 58. “Other HPV” includes other oncogenic HPV types. “HPV-negative” cancers are those that occur at anatomic sites in which HPV-associated cancers are often found, but HPV DNA was not detected.
¶ Compiled from population-based cancer registries that participate in the CDC National Program of Cancer Registries, and/or the National Cancer Institute's Surveillance, Epidemiology, and End Results Program and meet the criteria for high data quality for all years 2012–2016, covering 100% of the U.S. population.
** The estimated number of HPV-attributable cancers was calculated by multiplying the number of HPV-associated cancer cases by the percentage of each cancer type attributable to HPV. The total of HPV attributable cancers was the sum of cancers attributable to types targeted by 9vHPV and other HPV types. HPV-negative counts were the difference of the total count and the HPV-attributable counts. Estimates were rounded to the nearest 10; counts <10 are not displayed.